Roche Holding AG

Roche Holding AG

CHF270
4.2 (1.58%)
London Stock Exchange
CHF, CH
Drug Manufacturers - General

0QQ6.L Price Chart

Basic
Market CapCHF224.48B
PriceCHF270
52 Week Range236.0-317.4
Beta0.14
Margins
Gross Profit Margin73.61%
Operating Profit Margin29.72%
Net Profit Margin17.79%
Valuation (TTM)
P/E Ratio19.13
Price to Sales Ratio3.39
Price to Book Ratio7.02
PEG Ratio0.19

Industry

Drug Manufacturers - General

Sector

Healthcare

Full-Time Employees

103,605

IPO Date

2014-03-07T00:00:00.000Z

Description

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.

Phone

41 61 688 11 11

Address

Konzern Hauptsitz, Basel, 4070, CH

CIK